Ï㽶ÊÓƵ

Journal Article

1. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma, 1-4. ()
2. Siddiqui NS, Klein A, Godara A, Buchsbaum RJ, Hughes MC (2022). Predicting In-Hospital Mortality After Acute Myeloid Leukemia Therapy: Through Supervised Machine Learning Algorithms. JCO Clin Cancer Inform, 6, e2200044. ()
3. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol, 109(5), 559-565. ()
4. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48. ()
5. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D (2022). A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol, 9(10), e716-e719. ()
6. Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo R (2022). Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surg Neurol Int, 13, 12. ()
7. Alderuccio JP, Olszewski AJ, Evens AM, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, DAngelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K (2021). HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood Adv, 5(14), 2852-2862. ()
8. Godara A, Riesenburger RI, Zhang DX, Varga C, Fogaren T, Siddiqui NS, Yu A, Wang A, Mastroianni M, Dowd R, Nail TJ, McPhail ED, Kurtin PJ, Theis JD, Toskic D, Arkun K, Pilichowska M, Kryzanski J, Patel AR, Comenzo R (2021). Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid, 28, 1-8. ()
9. Zayac AS, Evens AM, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, DAngelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ (2021). Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica, 106(7), 1932-1942. ()
10. George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R (2021). Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. Clin Neurol Neurosurg, 206, 106708. ()
11. Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew P (2021). Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. J Clin Transl Sci, 5(1), e146. ()
12. Godara A, Siddiqui NS, Munigala S, Dhawan R, Kansagra AJ, Rapoport AP, Yared JA, Dahiya S (2020). Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation. JCO Oncol Pract, 17(3), e355-e368. ()
13. George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R (2020). Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis. J Clin Neurosci, 84, 33-37. ()
14. Godara A, Palladini G (2020). Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis. Hematol Oncol Clin North Am, 34(6), 1145-1159. ()
15. Saif MW, Hachem H, Purvey S, Hamal R, Zhang L, Siddiqui NS, Godara A, Diasio RB (2020). Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice. Arch Pharmacol Ther, 2(1), 6-8. ()

Review

1. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin GR (2023). Multiple Myeloma in Young Patients: A Scoping Review. [Review]. Clin Lymphoma Myeloma Leuk, 24(1), 15-22. ()

Case Report

1. Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo R (2022). Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surg Neurol Int, 13, 12. ()
2. Godara A, Migliozzi DR, Pilichowska M, Goyal N, Varga C, Gordon CE (2020). Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post-Kidney Transplant: A Case Report. Kidney Med, 2(5), 652-656. ()

Letter

1. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. [Letter to the editor]. Leuk Lymphoma, 65(9), 1362-1365. ()
2. Zhang Y, Godara A, Pan S, Toskic D, Mann H, Sborov D, Comenzo R, Kansagra A (2022). Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma. [Letter to the editor]. Ann Hematol, 101(9), 2119-2121. ()
3. Godara A, Toskic D, Albanese J, Rosenthal B, Siddiqui NS, Kugelmass A, Zhou P, Fogaren T, Varga C, Landau HJ, Comenzo RL (2020). Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis. [Letter to the editor]. Am J Hematol, 96(1), E20-E23. ()

Other

1. Hachem H, Godara A, Schroeder C, Fein D, Mann H, Lawlor C, Marshall J, Klein A, Poutsiaka D, Breeze JL, Joshi R, Mathew P (2021). Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. medRxiv. United States. ()

Huntsman Cancer Institute News

• Ask an Expert: What is Amyloidosis?

Podcasts

• What Treatments Are Most Effective for Multiple Myeloma?
• What is Amyloidosis and How is it Treated?